Intracerebral infusion of antisense oligonucleotides into prion-infected mice

Molecular Therapy Nucleic Acids

Volumn 1, Issue 2, 2012, Pages

  Friberg, Karah Nazor ^a   Hung, Gene ^b   Wancewicz, Ed ^b   Giles, Kurt ^a   Black, Chris ^b   Freier, Sue ^b   Bennett, Frank ^b   DeArmond, Stephen J ^a,c   Freyman, Yevgeniy ^a   Lessard, Pierre ^a   Ghaemmaghami, Sina ^a   Prusiner, Stanley B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868351310     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2011.6     Document Type: Article

References (23)

1. Tilly, G, Chapuis, J, Vilette, D, Laude, H and Vilotte, JL (2003). Efficient and specific down-regulation of prion protein expression by RNAi. Biochem Biophys Res Commun 305: 548-551. (Pubitemid 36579265)
2. Daude, N, Marella, M and Chabry, J (2003). Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 116(Pt 13): 2775-2779. (Pubitemid 36857228)
3. Pfeifer, A, Eigenbrod, S, Al-Khadra, S, Hofmann, A, Mitteregger, G, Moser, M et al. (2006). Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 116: 3204-3210. (Pubitemid 44878634)
4. White, MD, Farmer, M, Mirabile, I, Brandner, S, Collinge, J and Mallucci, GR (2008). Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 105: 10238-10243.
5. Kocisko, DA, Vaillant, A, Lee, KS, Arnold, KM, Bertholet, N, Race, RE et al. (2006). Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother 50: 1034-1044. (Pubitemid 43327809)
6. Karpuj, MV, Giles, K, Gelibter-Niv, S, Scott, MR, Lingappa, VR, Szoka, FC et al. (2007). Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells. Mol Med 13: 190-198. (Pubitemid 46944962)
7. Mallucci, G, Dickinson, A, Linehan, J, Klöhn, PC, Brandner, S and Collinge, J (2003). Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871-874. (Pubitemid 37339628)
8. Safar, JG, DeArmond, SJ, Kociuba, K, Deering, C, Didorenko, S, Bouzamondo-Bernstein, E et al. (2005). Prion clearance in bigenic mice. J Gen Virol 86(Pt 10): 2913-2923. (Pubitemid 41410483)
9. Bennett, CF and Swayze, EE (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50: 259-293.
10. Wu, H, Lima, WF, Zhang, H, Fan, A, Sun, H and Crooke, ST (2004). Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 279: 17181-17189. (Pubitemid 38560475)
11. Tamgüney, G, Francis, KP, Giles, K, Lemus, A, DeArmond, SJ and Prusiner, SB (2009). Measuring prions by bioluminescence imaging. Proc Natl Acad Sci USA 106: 15002-15006.
12. Sethi, S, Lipford, G, Wagner, H and Kretzschmar, H (2002). Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 360: 229-230. (Pubitemid 34804655)
13. Smith, RA, Miller, TM, Yamanaka, K, Monia, BP, Condon, TP, Hung, G et al. (2006). Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116: 2290-2296. (Pubitemid 44162339)
14. Prusiner, SB, Groth, D, Serban, A, Koehler, R, Foster, D, Torchia, M et al. (1993). Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti- PrP antibodies. Proc Natl Acad Sci USA 90: 10608-10612. (Pubitemid 23347091)
15. Büeler, H, Raeber, A, Sailer, A, Fischer, M, Aguzzi, A and Weissmann, C (1994). High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med 1: 19-30.
16. Sandberg, MK, Al-Doujaily, H, Sharps, B, Clarke, AR and Collinge, J (2011). Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470: 540-542.
17. Cheruvallath, ZS, Cole, DL and Ravikumar, VT (2003). A novel solid support for synthesis of oligonucleotide 3'-phosphorothioate monoesters. Bioorg Med Chem Lett 13: 281-284. (Pubitemid 35441352)
18. McKay, RA, Miraglia, LJ, Cummins, LL, Owens, SR, Sasmor, H and Dean, NM (1999). Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem 274: 1715-1722.
19. Drygin, D, Barone, S and Bennett, CF (2004). Sequence-dependent cytotoxicity of secondgeneration oligonucleotides. Nucleic Acids Res 32: 6585-6594.
20. Ghaemmaghami, S, Phuan, PW, Perkins, B, Ullman, J, May, BC, Cohen, FE et al. (2007). Cell division modulates prion accumulation in cultured cells. Proc Natl Acad Sci USA 104: 17971-17976. (Pubitemid 350210805)
21. Taraboulos, A, Jendroska, K, Serban, D, Yang, S-L, DeArmond, SJ and Prusiner, SB (1992). Regional mapping of prion proteins in brains. Proc Natl Acad Sci USA 89: 7620-7624.
22. Muramoto, T, Kitamoto, T, Tateishi, J and Goto, I (1992). The sequential development of abnormal prion protein accumulation in mice with Creutzfeldt-Jakob disease. Am J Pathol 140: 1411-1420.
23. Muramoto, T, DeArmond, SJ, Scott, M, Telling, GC, Cohen, FE and Prusiner, SB (1997). Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an alpha-helix. Nat Med 3: 750-755. (Pubitemid 27298718)